Skip to main content

Mannkind

MannKind Corporation is an American biopharmaceutical enterprise developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases. The company produces Afrezza, an FDA-approved inhaled rapid-acting human insulin utilizing its Technosphere dry-powder delivery technology, alongside manufacturing Tyvaso DPI (treprostinil) dry powder in collaboration with United Therapeutics. Principal revenues derive from commercial sales of Afrezza, collaboration manufacturing supply revenues for Tyvaso DPI, and royalty payments from United Therapeutics. Core end markets encompass endocrinology clinics, pulmonology hospital departments, diabetic patients, and pulmonary arterial hypertension (PAH) patients across the United States. MannKind Corporation holds a market-leading pioneer position in inhaled dry-powder biopharmaceutical delivery technology. The corporation is headquartered in Danbury, Connecticut, and its common stock trades on the Nasdaq Global Select Market.

2 of the funds FundTelligence covers report a position in Mannkind.

Legal name
Mannkind Corp
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Diabetes Technology, Insulin Delivery, Obesity & Metabolic Health

Funds holding Mannkind

Loading...